EU/3/16/1696

About

Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2020 on request of the sponsor.

On 14 July 2016, orphan designation (EU/3/16/1696) was granted by the European Commission to Cell Medica Ltd., United Kingdom, for autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo for the treatment of post-transplant lymphoproliferative disorder.

Key facts

Active substance
Autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo
Disease / condition
Treatment of post-transplantation lymphoproliferative disorders
Date of first decision
14/07/2016
Outcome
Withdrawn
EU designation number
EU/3/16/1696

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Cell Medica Ltd.
1 Canal Side Studios
8-14 St Pancras Way
London NW1 0QG
United Kingdom
Tel. +44 (0)20 7554 4070
E-mail: info@cellmedica.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating